Deletion of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is found in approximately 30% of DLBCL-type RT cases and is often acquired at the time of transformation, suggesting its pivotal role in driving RT in patients harboring this genetic lesion (Figure 1) [54]. This evidence concerns the gene CDKN2A and diffuse large B-cell lymphoma.